Table of Contents Author Guidelines Submit a Manuscript
Contrast Media & Molecular Imaging
Volume 2018, Article ID 3236829, 2 pages

Molecular Imaging in Targeted Therapeutics

1Department of Biochemistry, School of Medicine, Nankai University, Tianjin 300071, China
2Molecular Imaging Program at Stanford (MIPS), Canary Center at Stanford for Cancer Early Detection, Department of Radiology and Bio-X Program, School of Medicine, Stanford University, Stanford, CA 94305, USA
3School of Health Sciences, Purdue University, 550 Stadium Mall Drive, West Lafayette, IN 47907, USA
4Department of Nuclear Medicine, Nanjing First Hospital, Nanjing Medical University, Nanjing 210006, China

Correspondence should be addressed to Yuebing Wang; nc.ude.iaknan@gnibeuygnaw and Guoqiang Shao; moc.361@oahsgnaiqoug

Received 6 August 2018; Accepted 7 August 2018; Published 5 September 2018

Copyright © 2018 Yuebing Wang et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

With the rapid development of precision medicine, targeted therapy of tumors has made great advances. However, tumors of the same type were found to harbor different molecular alterations such as specific receptor, transporter, and cell expression levels before and even during the targeted therapy. Molecular imaging allows mapping of disease markers in vivo and understanding of disease biology. It promotes targeted therapy by therapeutic effect prediction, early response evaluation, and therapeutic regimen determination in preclinical and clinical settings. Molecular imaging technologies are being recognized as one of the most valuable tools in the field of precision medicine, which will make individual treatment decisions for better patient outcome care.

In this special issue, we focus on the recent advances of molecular imaging for targeted treatment strategies in precision medicine. Two review articles and nine original research articles are published in this special issue. The topics included synthesized targeting probes: PET, SPECT, MR, ultrasound, fluorescence, photoacoustics, and multimodal imaging.

L. P. Yao et al. reviewed the features of even blues and their potential applications in biomedicine. They pointed out that radiolabeled even blue and its derivatives will play an important role in clinical imaging of tumor lesions, evaluation of lymphatic disorders, and development of long-acting therapeutics. In the other review paper, A. C. Dupont et al. summarized the current inputs of PET in the assessment of therapeutic effectiveness in neurodegenerative diseases connected by common pathophysiological mechanisms. In addition, they discussed the opportunities for PET imaging to drive more personalized neuroprotective and therapeutic strategies.

Smart targeting probes were designed by the researchers in this special issue. Y. Y. Zhang et al. developed a smart nanoprobe named [131I] GNR-PEG-cRGD, which can be used for angiogenesis-targeted SPECT/CT imaging. This nanoprobe possesses a remarkable capacity for highly efficient photothermal conversion in the near-infrared region, suggesting its potential as a multifunctional theragnostic agent. Z. Q. Hu et al. designed NPs-SHP2 nanoparticles, which had high specificity to thyroid tumors in vitro and in vivo. Moreover, NPs-SHP2 could be activated by LIFU irradiation to enhance ultrasound molecular imaging in thyroid cancer model. In the study by X. B. Ma et al., GO-AuNS-DOTA-Gd was prepared and its physicochemical properties indicated that this probe could act as an efficient photosensitizer for photothermal therapy. Additionally, GO-AuNS-DOTA-Gd can be used for precisely delineating the tumor margin from normal tissues based on multimodality molecular imaging.

A new tracer [18F] AmBF3-TEG-ES was prepared by H. B. Huang et al. They showed that [18F] AmBF3-TEG-ES would be a potential PET imaging agent for the diagnosis of estrogen-dependent tumors. Similarly, X. Q. Du et al. investigated the differential diagnostic value of 18F-Alfatide II PET/CT between tuberculosis and lung cancer patients. Moreover, they analyzed the angiogenesis in sarcoidosis and chronic inflammations.

R. Nishii et al. also focus on PET imaging. They demonstrated that MeAIB-PET could provide better assessments for detecting malignant type brain tumors. In a differential diagnosis between low-grade and high-grade astrocytoma, MeAIB-PET is a useful diagnostic imaging tool, especially in evaluations using the T/N ratio.

Y. J. Liu et al. observed that positive neural correlations of respiratory amplitude were shown in anterior lobe and insula, while they were negative in prefrontal cortex and sensorimotor areas. Their findings revealed the involvement of cognitive, executive control, and sensorimotor processing in hypnosis for respiratory control.

G. Q. Shao et al. published two articles in this special issue. In one of the papers, they synthesized a novel 32P-CP-PLGA seeds which can control the release of entrapped 32P-CP particles. Their results demonstrated that 32P-CP-PLGA seeds are very promising for glioma brachytherapy, and 68Ga-3PRGD2 imaging shows great potential for early response evaluation of 32P-CP-PLGA seeds brachytherapy. In the other paper, they demonstrated that the 68Ga-PSMA-11 PET-CT imaging could invasively evaluate PSMA expression during PCa progression and tumor growth with % ID/cm3 (based on functional volume) as an important index. Low-dose 2-PMPA preadministration might be a choice to decrease kidney uptake of 68Ga-PSMA-11.

Conflicts of Interest

The editors declare that they have no conflicts of interest.


We are very grateful to all the authors for submitting their manuscripts to the special issue “Molecular Imaging in Targeted Therapeutics” as well as the professional reviewers for providing their helpful comments and suggestions. We thank the reviewers and authors for their time and efforts.

Yuebing Wang
Zhen Cheng
Shuang Liu
Guoqiang Shao